Lilly sues companies selling compounded Zepbound, Mounjaro
by
Contributor since / Followers
Contributor since / Followers
1 month ago
aprott/iStock via Getty Images
- Eli Lilly has filed lawsuits against three companies for continuing to sell compounded versions of tirzepatide, the active ingredient in its weight loss and type 2 diabetes meds Zepbound and Mounjaro.
- Compounded versions of drugs that still have patent protection are permitted if that med is in shortage. However, the drug giant noted that both of its tirzepatide treatments were taken off the U.S. FDA drug shortage list earlier in October.
- The companies named in the lawsuits are Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine of Nevada, Reuters reported.
- The news service said that a Lilly spokesperson expressed concern the companies are making false claims about the products’ efficacy and safety, and potentially misleading consumers about the data used to corroborate them.